Summary & Overview
HCPCS C9469: Triamcinolone Acetonide Extended‑Release Injection, 1 mg
HCPCS Level II code C9469 identifies a preservative-free, extended-release microsphere formulation of triamcinolone acetonide for injection (1 mg). The code captures a targeted corticosteroid product designed for prolonged local anti-inflammatory action, commonly used for intra-articular or periarticular management of pain and inflammation. Nationally, accurate coding for specialized formulations like this affects claims processing, provider reimbursement, and utilization monitoring across commercial and public payers.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the product, typical sites of service where the injection is administered, and benchmarking topics relevant to these payers. The publication summarizes coding implications, highlights where policy or coverage variation commonly occurs, and outlines the types of benchmarks and policy updates that affect billing and reimbursement for specialty injectable corticosteroids.
This summary helps revenue cycle, compliance, and clinical staff understand what HCPCS Level II code C9469 represents, why it matters in payer adjudication, and which areas—coverage criteria, site-of-service designation, and coding specificity—are most likely to influence claims outcomes.
Billing Code Overview
HCPCS Level II code C9469 represents an injection of triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg. This product is a corticosteroid formulation intended for local intra-articular or periarticular administration to provide extended anti-inflammatory effect through a microsphere delivery system.
Service Type: Injection; intra-articular or periarticular corticosteroid therapy
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgical center, where joint or soft-tissue injections are performed using sterile technique.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with chronic knee osteoarthritis presents to an orthopedic clinic with persistent joint pain and limited mobility despite conservative care (oral NSAIDs, physical therapy). After evaluation including history, focused physical exam, and recent knee radiographs confirming moderate-to-severe degenerative changes, the orthopedic surgeon and patient elect intra-articular injection of preservative-free, extended-release triamcinolone acetonide microspheres to provide prolonged local corticosteroid effect and symptom relief. The clinical workflow includes informed consent, allergy review, medication reconciliation, procedural timeout, sterile preparation of the injection site, optional local anesthetic, ultrasound or landmark-guided intra-articular needle placement, administration of the C9469 product (1 mg vial), post-procedure observation for immediate adverse effects, and documentation of lot number, amount administered, and patient response. Typical sites of service include outpatient physician offices, ambulatory surgery centers, and hospital outpatient departments where intra-articular corticosteroid injections are performed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a qualifying E/M is performed and documented on the same day as the injection |